ESPR · Esperion Therapeutics, Inc. · Stock research

Current Thesis

The ARCHIMED take-private has cleared its final binary. At the special virtual meeting on 2026-07-08, holders adopted the merger agreement with 135,326,793 shares for versus 22,750,628 against and 496,194 abstaining, on a 61.53% quorum (158,573,615 of 257,693,347 shares — roughly 85% of the shares that voted backed the deal). That was the last substantive gate: the HSR waiting period expired 2026-06-15 and German antitrust cleared ahead of it, so nothing but customary closing mechanics stands between here and a Q3-2026 close followed by Nasdaq delisting. Terms are fixed $3.16/share cash plus one non-tradeable CVR worth up to $100M aggregate (~$0.39/share) and the tape reflects it, with shares sitting on the cash number and the arb spread compressed to a few basis points. For a narrative-velocity mandate this is a completed special situation paying out in cash, not a setup with a leg to ride. Price is now a step function at $3.16 waiting to be extinguished at close.

Bullish and bearish views on Esperion Therapeutics, Inc.

The model's bull view on Esperion Therapeutics, Inc. (ESPR), in brief: Last binary cleared: the 2026-07-08 stockholder vote adopted the deal 135.3M for vs 22.8M against, removing the only remaining substantive condition. The bear view: Upside is contractually capped at $3.16 and the price already sits on that ceiling, so even the residual arb carry has gone a few basis points to a Q3 close. Both cases follow in full.

Bull Case

• Last binary cleared: the 2026-07-08 stockholder vote adopted the deal 135.3M for vs 22.8M against, removing the only remaining substantive condition.
• Both antitrust gates already done HSR waiting period expired 2026-06-15 (8-K), German antitrust approval obtained before the vote leaving only customary closing mechanics into a Q3-2026 close.
• Board-unanimous agreement signed 2026-05-01 with committed debt financing via Pharmakon Advisors funds; the DEFM14A is definitive, lowering financing-failure and re-cut risk.
• Financial sponsor with no overlapping cardiovascular franchise (ARCHIMED via Essence Parent Inc.), so the antitrust path was clean and has now landed.
• Free optionality in the CVR tail: $40M if bempedoic-acid (NEXLETOL/NEXLIZET) US net sales top $350M in 2027; $60M if ENBUMYST/bumetanide US net sales reach $160M in any single year through 2030.
• Underlying business is growing into the bid: Q1 2026 revenue $80.1M (+23% YoY; product $43.4M, collaboration $36.7M), net loss narrowed to $25.2M from $40.5M a year earlier.

Bear Case

• Upside is contractually capped at $3.16 and the price already sits on that ceiling, so even the residual arb carry has gone a few basis points to a Q3 close.
• The CVR probably pays little: bempedoic-acid US sales annualize to ~$174M off Q1's $43.4M, so the $40M 2027 tranche needs a near-double of run-rate to trigger; it reads as a lottery ticket rather than embedded value.
• Payoff is asymmetric the wrong way a financing or MAE surprise before close reverts the stock toward the ~$2.00 pre-announcement level (2026-04-30), roughly -37% against essentially no upside.
• Nothing left to compound: with the vote done and the spread near zero, the name is a cash placeholder returning nothing until it delists, pure opportunity cost while accelerating narratives run elsewhere.
• Q2 numbers, normally early August, are moot pre-close and may never print if the deal closes first no fundamental catalyst can re-rate the equity above the cash terms.

Setup & Price Structure

• One deal gap on 2026-05-01 from ~$2.00 into the low-$3s (+~55% session) is the entire move; the tape has been flat and pinned to $3.16 since, with the July vote passing without incident.
• 52-week range $0.95–$4.18; the $4.18 high predates the deal and is unreachable under fixed terms. Market cap ~$817M at the cash number, up to ~$1.1B total equity value counting the CVR and dilution.
• Volume has thinned to arb-grade the standard signature of a closed-spread merger name and options prints such as the 2026-07-01 "whale alert" screen are positioning noise around the payout rather than directional information.
• Trend tools carry no signal here: moving averages, RSI and EMAs are non-informative when price tracks deal-close probability instead of momentum. There is no higher-low base, only the $3.16 cap with a vanishing spread beneath it.

Catalyst Calendar (next 30 days)

• CVR effectiveness at close CVR terms lock at completion, no interim milestone payment is due (2027 net-sales test for bempedoic acid; single-year tests for bumetanide through 2030).
• Q2 2026 earnings historically early August (~2026-08-04, est.), but likely moot or unheld if the merger closes first; not a tradeable print pre-close.

Elapsed catalysts

• Merger close & Nasdaq delisting expected Q3 2026 and likely imminent now that the 2026-07-08 vote passed and every regulatory gate is cleared; no firm effective date announced (~late July 2026, est.). _(passed 11d ago)_

What Would Change Our Mind

• A daily close clearly above $3.16 say above $3.25, beyond the ~$0.39 CVR value would signal a topping or competing bid and re-open genuine upside; that is the only path to a tradeable long here.
• A daily close below $3.00 would flag the market pricing real deal-break risk (financing pull, material adverse change, closing-condition failure), a route back toward the ~$2.00 pre-announcement level.
• A definitive 8-K announcing the effective date and final CVR mechanics closes the book: cash and delisting, nothing left to trade.
• Any competing-bidder headline or an ARCHIMED/Pharmakon financing wobble is the only news that reintroduces two-way risk into an otherwise settled outcome.

Correlation Notes

• Idiosyncratic: post-vote, ESPR trades on deal-close probability, not on biotech beta, rates, or the cardiovascular tape. XBI/IBB swings barely register against a $3.16 contractual anchor.
• CVR value is the one live fundamental link it tracks bempedoic-acid (NEXLETOL/NEXLIZET) and bumetanide (ENBUMYST) US net-sales trajectories, which respond to script trends and ex-US collaboration economics, but those only matter to holders after close.
• The read to peers is narrow: it marks a valuation floor for small-cap cardiometabolic names (a sponsor paid a 58% premium for a growing but unprofitable commercial biotech) without implying directional beta for the group.